Omega-3 Compound Reduces Inflammation in Cystic Fibrosis Patients in New Pilot Study

By Jennifer Prince

A marine omega-3 compound comprising a docosahexaenoic acid (DHA) sn1-monoacylglyceride (MAG-DHA) may act as an anti-inflammatory for subjects with cystic fibrosis, according to a new pilot study1 published in the journal Marine Drugs. In the study, MaxSimil (Neptune Wellness Solutions; Laval, QC, Canada) increased omega-3 red blood cell levels, helped moderate the ratio of arachidonic acid (AA) to docosahexaenoic acid, and reduced key inflammatory biomarkers in subjects with cystic fibrosis. Continue reading Omega-3 Compound Reduces Inflammation in Cystic Fibrosis Patients in New Pilot Study

Vitamin D3 deficiency and its association with nasal polyposis in patients with cystic fibrosis

This trial ascertained if the deficiency of vitamin D3 (VD3) correlated with the presence of nasal polyposis (NP) in patients with cystic fibrosis (CF) and patients with chronic rhinosinusitis (CRS). VD3 deficiency appeared to be related to the presence of nasal polyps in the patients with CRS and in the patients with CF in a similar manner. It was inferred that the lower the level of serum VD3, the more severe the mucosal disease was disclosed in the imaging studies and the more frequent microbial colonization of the patients with CF and the patients with CRS. Continue reading Vitamin D3 deficiency and its association with nasal polyposis in patients with cystic fibrosis

Cystic Fibrosis Patients Shouldn’t Skip Supplements

http://www.pharmacytimes.com/

Improved diagnosis and treatment has extended cystic fibrosis (CF) patients’ life expectancy into adulthood. Continue reading Cystic Fibrosis Patients Shouldn’t Skip Supplements